Zentalis up on dose selection study data for ovarian cancer therapy

Zentalis Pharmaceuticals

06/06/2023 13:01

** Shares of cancer drug developer Zentalis Pharmaceuticals
Inc  ZNTL.O  up 3.3% at $25.49 premarket
    ** Co says cancer therapy azenosertib shows double efficacy
in intermittent dosing regime vs continuous dosing in an
early-stage study in patients with a certain type of ovarian
cancer 
    ** Study finds overall response rate at 36.8% in weekly
administration schedule with 5 days on, 2 days off vs 19.2% in
continuous dosing regime
    ** Intermittent dosing maintained safety profile, while
improving tolerability to the treatment
    ** Co plans to update efficacy data from early-stage dose
optimization study 
    ** Three mid-stage studies enrolling patients; co to give
further updates in H2
    ** Stock up 22.5% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))